参考文献 [1] Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med, 2013,39(2):165-228. [2] Michel MS, Trojan L, Rassweiler JJ. Complications in percutaneous nephrolithotomy. Eur Urol, 2007,51(4):899-906; discussion 906. [3] Vorrakitpokatorn P, Permtongchuchai K, Raksamani EO, et al. Perioperative complications and risk factors of percutaneous nephrolithotomy. J Med Assoc Thai, 2006,89(6):826-833. [4] Mariappan P, Smith G, Bariol SV, et al. Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. J Urol, 2005,173(5):1610-1614. [5] Li K, Liu C, Zhang X, et al. Risk factors for septic shock after mini-percutaneous nephrolithotripsy with holmium laser. Urology, 2013,81(6):1173-1176. [6] 那彦群, 孙颖浩. 中国泌尿外科疾病诊断治疗指南. 北京:人民卫生出版社,2014.428-429. [7] Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis, 2013,13(5):426-435. [8] Brunkhorst FM, Wegscheider K, Forycki ZF, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med, 2000,26 Suppl 2:S148-152. [9] Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful. Crit Care Clin, 2006,22(3):503-519, ix-x. [10] 邓刚, 马立彬, 居翔, 等. 血清降钙素原在上尿路腔内碎石术后脓毒血症诊治中的应用研究. 中华医院感染学杂志, 2013,23(24):5924-5926. [11] Zheng J, Li Q, Fu W, et al. Procalcitonin as an early diagnostic and monitoring tool in urosepsis following percutaneous nephrolithotomy. Urolithiasis, 2014. [12] Hatherill M, Tibby SM, Sykes K, et al. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child, 1999,81(5):417-421. [13] Fioretto JR, Martin JG, Kurokawa CS, et al. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res, 2010,59(8):581-586. [14] Sugimoto K, Shimizu N, Matsumura N, et al. Procalcitonin as a useful marker to decide upon intervention for urinary tract infection. Infect Drug Resist, 2013,6:83-86. [15] O'Keeffe NK, Mortimer AJ, Sambrook PA, et al. Severe sepsis following percutaneous or endoscopic procedures for urinary tract stones. Br J Urol, 1993,72(3):277-283. [16] Korets R, Graversen JA, Kates M, et al. Post-percutaneous nephrolithotomy systemic inflammatory response: a prospective analysis of preoperative urine, renal pelvic urine and stone cultures. J Urol, 2011,186(5):1899-1903. [17] 姚剑, 顾金华. 上尿路结石的细菌学研究及其临床意义. 中华泌尿外科杂志, 2005,26(8):542-544. [18] Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis. Crit Care, 2013,17(6):R291. [19] Xu RY, Liu HW, Liu JL, et al. Procalcitonin and C-reactive protein in urinary tract infection diagnosis. BMC Urol, 2014,14:45. [20] Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet, 2010,375(9713):463-474.
|